Meta-analysis of clinical trials with statins (HMGCR inhibitors) have shown an increase in T2D incidence [44–46], which seems to be dose related [35,43] and that affects insulin resistant individuals in a disproportionate way [38]. The gene discussed is INS; the disease is type 2 diabetes mellitus.